Table 4 Diagnosis-specific adjusted means of total costs over 12 months after baseline, insurer and secondary societal perspectives
| Â | HOM group | CON group | Â | |||
|---|---|---|---|---|---|---|
Diagnosis | N Cost utilization | Adj. mean (€) (95% CI) | N Cost utilization | Adj. mean (€) (95% CI) | Group Δ* | p-value†|
Insurer perspective (primary cost outcome) | ||||||
 Migraine/headache | 422 | 1654.42 (1309.80–1999.04) | 265 | 1231.30 (839.57–1623.02) | 423.13 | < 0.001 |
 Allergic rhinitis | 316 | 1137.50 (880.82–1394.17) | 187 | 1038.28 (748.78–1327.79) | 99.22 | 0.220 |
 Asthma | 123 | 1463.28 (938.27–1988.29) | 80 | 722.83 (116.94–1328.73) | 740.45 | < 0.001 |
 Atopic dermatitis | 229 | 1269.32 (962.23–1576.40) | 104 | 1129.83 (763.50–1496.17) | 139.49 | 0.250 |
 Depression | 452 | 1974.63 (1703.83–2245.43) | 341 | 1553.96 (1241.84–1866.08) | 420.67 | < 0.001 |
Societal perspective | ||||||
 Migraine/headache | 422 | 4938.64 (2358.01–7519.28) | 265 | 5010.48 (2077.35–7943.61) | −71,84 | 0.924 |
 Allergic rhinitis | 316 | 3073.44 (1125.04–5021.84) | 187 | 3274.15 (1074.55–5473.74) | −200,71 | 0.744 |
 Asthma | 123 | 3022.62 (−43.81–6089.04) | 80 | 1285.69 (−2244.58–4815.95) | 1736,93 | 0.157 |
 Atopic dermatitis | 229 | 7353.94 (5070.56–9637.31) | 104 | 7536.04 (4812.85–10,259.24) | −182,1 | 0.839 |
 Depression | 452 | 9402.39 (6182.19–12,622.59) | 341 | 7207.43 (3499.95–10,914.90) | 2194,96 | 0.078 |